[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].
Burgaleta
C
C
Servicio de Hematología, Hospital Ramón y Cajal, Madrid.
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control / Q000628:therapy; D016026:Bone Marrow Transplantation; D002177:Candidiasis / Q000517:prevention & control / Q000628:therapy; D002178:Candidiasis, Chronic Mucocutaneous / Q000517:prevention & control / Q000628:therapy; D002986:Clinical Trials as Topic; D003453:Cryptococcosis / Q000517:prevention & control / Q000628:therapy; D004311:Double-Blind Method; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D009091:Mucormycosis / Q000517:prevention & control / Q000628:therapy; D009181:Mycoses / Q000517:prevention & control / Q000628:therapy*; D009503:Neutropenia / Q000150:complications* / Q000209:etiology; D009761:Nystatin / Q000627:therapeutic use; D011322:Primary Prevention; D012008:Recurrence; D012189:Retrospective Studies
D000935:Antifungal Agents; D009761:Nystatin; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D007654:Ketoconazole